{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04706923",
            "orgStudyIdInfo": {
                "id": "BCV-PA01"
            },
            "organization": {
                "fullName": "SymBio Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection",
            "officialTitle": "A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection or Cytomegalovirus Infection",
            "acronym": "ATHENA",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "a-phase-study-of-iv-bcv-in-subjects-with-adenovirus-infection"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2021-08-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-09-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-09-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-01-05",
            "studyFirstSubmitQcDate": "2021-01-11",
            "studyFirstPostDateStruct": {
                "date": "2021-01-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-20",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "SymBio Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV",
            "detailedDescription": "This is a Phase IIa, open-label, multiple ascending dose confirmation, multicenter study to evaluate the safety and tolerability of intravenous Brincidofovir (BCV, SyB V-1901) 0.2 mg/kg, 0.3 mg/kg, or 0.4 mg/kg dosed BIW or 0.4 mg/kg dosed QW (Cohorts 1 to 4) in adult and pediatric subjects with AdV viremia, and IV BCV in subjects with CMV."
        },
        "conditionsModule": {
            "conditions": [
                "Adenovirus Infections",
                "Cytomegalovirus Infection"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 52,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "BCV 0.2mg/kg BIW",
                    "type": "EXPERIMENTAL",
                    "description": "BCV: 0.2 mg/kg administered as a continuous IV infusion over 2 hours",
                    "interventionNames": [
                        "Drug: BCV"
                    ]
                },
                {
                    "label": "BCV 0.3mg/kg BIW",
                    "type": "EXPERIMENTAL",
                    "description": "BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours",
                    "interventionNames": [
                        "Drug: BCV"
                    ]
                },
                {
                    "label": "BCV 0.4 mg/kg BIW",
                    "type": "EXPERIMENTAL",
                    "description": "BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours",
                    "interventionNames": [
                        "Drug: BCV"
                    ]
                },
                {
                    "label": "BCV 0.4 mg/kg QW",
                    "type": "EXPERIMENTAL",
                    "description": "BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours",
                    "interventionNames": [
                        "Drug: BCV"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BCV",
                    "description": "Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.",
                    "armGroupLabels": [
                        "BCV 0.2mg/kg BIW",
                        "BCV 0.3mg/kg BIW",
                        "BCV 0.4 mg/kg BIW",
                        "BCV 0.4 mg/kg QW"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety will be evaluated based on incidence and severity of Adverse Events, Serious Adverse Events and laboratory assessments.",
                    "description": "Safety will be evaluated based on incidence and severity of Adverse Events, Serious Adverse Events and laboratory assessments.",
                    "timeFrame": "From initiation of BCV administration up to 19 weeks"
                },
                {
                    "measure": "Antiviral Effects",
                    "description": "Change from baseline AdV viremia in plasma measured on Day 1 and weekly throughout the study.",
                    "timeFrame": "From initiation of BCV administration up to 9 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female, aged 2 months and older at the time of informed consent.\n* AdV DNA viremia \\>10,000 copies/mL from a single sample, or 2 samples greater than 48 hours apart with the second result higher than the first and both greater than 1000 copies/mL, from the data obtained from the designated central virology laboratory of the local laboratory using the blood sample(s) collected informed consent has been obtained and within 7 days prior to Day 1 (AdV DNA viremia results collected within the 7 day window, but prior to consent may be used if the Informed Consent Form (ICF) signed by the subject provides approval) . CMV viremia with or without evidence of tissue invasive CMV disease. For laboratory results that are generated in units other than copies/mL or IU/mL, please refer to the testing laboratory for guidance on the appropriate conversion calculation.\n* Either (a) have disseminated AdV disease or (b) have an underlying immunocompromised state, and have asymptomatic AdV infection or localized AdV disease.\n* In the judgment of the investigator, be in a serious condition to be treated with intravenous cidofovir for AdV.\n\nExclusion Criteria:\n\n* Subjects who weigh \u2265120 kg.\n* NIH/NCI CTCAE (United States \\[US\\] National Institutes of Health \\[NIH\\]/National Cancer Institute) Grade 2 or higher diarrhea (i.e., increase of \u2265 4 stools per day over usual pre-transplant stool output) within 7 days prior to Day 1.\n* NIH Stage 4 acute GVHD of the skin (i.e., generalized erythroderma with bullous formation) within 7 days prior to Day 1.\n* NIH Stage 2 or higher acute GVHD of the liver function (i.e., bilirubin \\>3 mg/dL \\[SI: \\>51 \u03bcmol/L\\]) within 7 days prior to Day 1.\n* NIH Stage 2 or higher acute GVHD of the gut (i.e., diarrhea \\>556 mL/m2/day for pediatric subjects \\[or \\>1000 mL/day for young adults as applicable, at centers in the United States only\\], or severe abdominal pain with or without ileus) within 7 days prior to Day 1.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "2 Months",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Kohji Shimasaki",
                    "role": "CONTACT",
                    "phone": "+81-3-6684-6616",
                    "email": "MedInfo@symbiopharma.com"
                },
                {
                    "name": "Rochelle Maher",
                    "role": "CONTACT",
                    "phone": "+1-917-656-6951",
                    "email": "rmaher@symbiopharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90027",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "COMPLETED",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "COMPLETED",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60637",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "University of Nebraska Medical Center",
                    "status": "RECRUITING",
                    "city": "Omaha",
                    "state": "Nebraska",
                    "zip": "68198",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.25626,
                        "lon": -95.94043
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "Cincinnati Children's Hospital Medical Center",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "St. Jude Children's Research Hospital",
                    "status": "RECRUITING",
                    "city": "Memphis",
                    "state": "Tennessee",
                    "zip": "38105",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.14953,
                        "lon": -90.04898
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Related Info",
                    "url": "https://www.symbiopharma.com/en/pipeline/overview.html"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000003141",
                    "term": "Communicable Diseases"
                },
                {
                    "id": "D000000257",
                    "term": "Adenoviridae Infections"
                },
                {
                    "id": "D000003586",
                    "term": "Cytomegalovirus Infections"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000004266",
                    "term": "DNA Virus Infections"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000006566",
                    "term": "Herpesviridae Infections"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10283",
                    "name": "Infections",
                    "asFound": "Infection",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "asFound": "Infection",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6791",
                    "name": "Cytomegalovirus Infections",
                    "asFound": "Cytomegalovirus Infections",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3610",
                    "name": "Adenoviridae Infections",
                    "asFound": "Adenovirus Infection",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7442",
                    "name": "DNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M9643",
                    "name": "Herpesviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "T1720",
                    "name": "Cytomegalic Inclusion Disease",
                    "asFound": "Cytomegalovirus Infections",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M351625",
                    "name": "Brincidofovir",
                    "relevance": "LOW"
                },
                {
                    "id": "M1785",
                    "name": "Cidofovir",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}